These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 22909145)

  • 1. Bioequivalence evaluation of a folate-supplemented oral contraceptive containing ethinylestradiol/drospirenone/levomefolate calcium versus ethinylestradiol/drospirenone and levomefolate calcium alone.
    Wiesinger H; Eydeler U; Richard F; Trummer D; Blode H; Rohde B; Diefenbach K
    Clin Drug Investig; 2012 Oct; 32(10):673-84. PubMed ID: 22909145
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bioequivalence study of an oral contraceptive containing ethinylestradiol/drospirenone/levomefolate calcium relative to ethinylestradiol/drospirenone and to levomefolate calcium alone.
    Blode H; Klipping C; Richard F; Trummer D; Rohde B; Diefenbach K
    Contraception; 2012 Feb; 85(2):177-84. PubMed ID: 22067789
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EE-drospirenone-levomefolate calcium versus EE-drospirenone + folic acid: folate status during 24 weeks of treatment and over 20 weeks following treatment cessation.
    Diefenbach K; Trummer D; Ebert F; Lissy M; Koch M; Rohde B; Blode H
    Int J Womens Health; 2013; 5():149-63. PubMed ID: 23610531
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Folate status and homocysteine levels during a 24-week oral administration of a folate-containing oral contraceptive: a randomized, double-blind, active-controlled, parallel-group, US-based multicenter study.
    Bart S; Marr J; Diefenbach K; Trummer D; Sampson-Landers C
    Contraception; 2012 Jan; 85(1):42-50. PubMed ID: 22067790
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Beyaz®: an oral contraceptive fortified with folate.
    Fruzzetti F
    Womens Health (Lond); 2012 Jan; 8(1):13-9. PubMed ID: 22171769
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comprehensive evaluation of Safyral(®) 2012.
    Nelson AL
    Womens Health (Lond); 2012 Nov; 8(6):619-33. PubMed ID: 23181528
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Confirmation of the drug-drug interaction potential between cobicistat-boosted antiretroviral regimens and hormonal contraceptives.
    Majeed SR; West S; Ling KH; Das M; Kearney BP
    Antivir Ther; 2019; 24(8):557-566. PubMed ID: 31933482
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The combined oral contraceptive pill containing drospirenone and ethinyl estradiol plus levomefolate calcium.
    Rapkin RB; Creinin MD
    Expert Opin Pharmacother; 2011 Oct; 12(15):2403-10. PubMed ID: 21877996
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A historical cycle control comparison of two drospirenone-containing combined oral contraceptives: ethinylestradiol 30 μg/drospirenone 3 mg administered in a 21/7 regimen versus ethinylestradiol 20 μg/drospirenone 3 mg administered in a 24/4 regimen.
    Marr J; Gerlinger C; Kunz M
    Eur J Obstet Gynecol Reprod Biol; 2012 May; 162(1):91-5. PubMed ID: 22391750
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of empagliflozin on the steady-state pharmacokinetics of ethinylestradiol and levonorgestrel in healthy female volunteers.
    Macha S; Mattheus M; Pinnetti S; Woerle HJ; Broedl UC
    Clin Drug Investig; 2013 May; 33(5):351-7. PubMed ID: 23512637
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transfer of drospirenone to breast milk after a single oral administration of 3 mg drospirenone + 30 microg ethinylestradiol to healthy lactating women.
    Blode H; Foidart JM; Heithecker R
    Eur J Contracept Reprod Health Care; 2001 Sep; 6(3):167-71. PubMed ID: 11763981
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative pharmacokinetic estimates of drospirenone alone and in combination with ethinyl estradiol after single and repeated oral administration in healthy females.
    Richter WH; Koytchev R; Kirkov V; Merki G; Colli E; Regidor PA
    Contraception; 2020 Feb; 101(2):137-143. PubMed ID: 31758920
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Individualization of low-dose oral contraceptives. Pharmacological principles and practical indications for oral contraceptives].
    Cianci A; De Leo V
    Minerva Ginecol; 2007 Aug; 59(4):415-25. PubMed ID: 17923832
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A 1-year pharmacokinetic investigation of a novel oral contraceptive containing drospirenone in healthy female volunteers.
    Blode H; Wuttke W; Loock W; Röll G; Heithecker R
    Eur J Contracept Reprod Health Care; 2000 Dec; 5(4):256-64. PubMed ID: 11245553
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of rifampin and rifabutin on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive.
    Barditch-Crovo P; Trapnell CB; Ette E; Zacur HA; Coresh J; Rocco LE; Hendrix CW; Flexner C
    Clin Pharmacol Ther; 1999 Apr; 65(4):428-38. PubMed ID: 10223781
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The bioequivalence of the contraceptive steroids ethinylestradiol and drospirenone is not affected by co-administration of dehydroepiandrosterone.
    Zimmerman Y; Wouters W; Coelingh Bennink HJ
    Eur J Contracept Reprod Health Care; 2013 Jun; 18(3):206-14. PubMed ID: 23550808
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of steady-state ambrisentan on the pharmacokinetics of a single dose of the oral contraceptive norethindrone (norethisterone) 1 mg/ethinylestradiol 35 microg in healthy subjects: an open-label, single-sequence, single-centre study.
    Spence R; Mandagere A; Walker G; Dufton C; Boinpally R
    Clin Drug Investig; 2010; 30(5):313-24. PubMed ID: 20384387
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ethinylestradiol/drospirenone: a review of its use as an oral contraceptive.
    Keam SJ; Wagstaff AJ
    Treat Endocrinol; 2003; 2(1):49-70. PubMed ID: 15871554
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and tolerability of a monophasic oral contraceptive containing ethinylestradiol and drospirenone.
    Huber J; Foidart JM; Wuttke W; Merki-Feld GS; The HS; Gerlinger C; Schellschmidt I; Heithecker R
    Eur J Contracept Reprod Health Care; 2000 Mar; 5(1):25-34. PubMed ID: 10836660
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of zonisamide on the pharmacokinetics and pharmacodynamics of a combination ethinyl estradiol-norethindrone oral contraceptive in healthy women.
    Griffith SG; Dai Y
    Clin Ther; 2004 Dec; 26(12):2056-65. PubMed ID: 15823769
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.